E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028537 |
E.1.2 | Term | Myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074689 |
E.1.2 | Term | Post polycythemia vera myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074690 |
E.1.2 | Term | Post essential thrombocythemia myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074691 |
E.1.2 | Term | Post polycythaemia vera myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10074692 |
E.1.2 | Term | Post essential thrombocythaemia myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10077161 |
E.1.2 | Term | Primary myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate preliminary efficacy of itacitinib (INCB039110) on spleen volume reduction (SVR) from baseline at Week 24 in the 2 following cohorts of MF subjects: • Cohort A: in combination in subjects with ruxolitinib low dose (less than 20mg daily). • Cohort B: as monotherapy in subjects who progressed (per revised European LeukemiaNet [ELN] 2013 response criteria for MF) after initial reduction in spleen on ruxolitinib or discontinued for hematologic toxicities. |
|
E.2.2 | Secondary objectives of the trial |
- To evaluate preliminary safety and tolerability of itacitinib alone. - To evaluate preliminary safety and tolerability of itacitinib in combination with ruxolitinib. - To evaluate preliminary efficacy of itacitinib alone or in combination with ruxolitinib on SVR from baseline at Week 12. - To evaluate preliminary efficacy of itacitinib alone or in combination with ruxolitinib on spleen length reduction from baseline at Week 12 and Week 24. - To evaluate preliminary efficacy of itacitinib alone or in combination with ruxolitinib with respect to MF symptoms at Week 12 and Week 24. - To evaluate preliminary efficacy of itacitinib using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. - To assess the pharmacokinetics (PK) of itacitinib and ruxolitinib. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Cohort A only • Receiving ruxolitinib dose of less than 20 mg daily with no dose increase or no dose modification in the last 8 weeks before screening visit. Cohort B only • Must have had initial reduction in spleen on ruxolitinib treatment (response is defined by any spleen length or volume reduction, by palpation or MRI/CT assessment, from baseline while on previous ruxolitinib treatment per IWG-MRT ELN 2013 guidelines): - Followed by documented evidence of progression in spleen length or volume OR - Discontinued ruxolitinib for hematologic toxicities, after the initial reduction in spleen length or volume. All subjects • Men and women, aged 18 years or older. • Confirmed diagnosis of PMF, PPV-MF, or PET-MF according to revised WHO 2016 criteria. • Must have palpable spleen of ≥ 5 cm below the left subcostal margin on physical examination at the screening visit. (If spleen is not palpable due to body habitus, spleen enlargement must be documented by other means [eg, ultrasound or MRI] and study sponsor medical monitor be contacted for acceptance). |
|
E.4 | Principal exclusion criteria |
All subjects • Lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better. • Previous treatment with itacitinib or JAK1 inhibitors (JAK1/JAK2 inhibitor ruxolitinib is permitted). |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change and percentage change in SVR as measured by magnetic resonance imaging [MRI] (computed tomography [CT] scan in subjects who are not candidates for MRI or when MRI is not readily available) at Week 24 when compared with baseline. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Safety and tolerability through assessment of frequency, severity, and duration of AEs; changes in clinical safety assessments; and changes in clinical laboratory parameters. - Change and percentage in SVR from baseline through Week 12 as measured by MRI (or CT scan in applicable subjects). - Change and percentage change on spleen length reduction from baseline through Week 12 and Week 24 as measured by palpation. - Change and percentage change in TSS from baseline through Week 12 and Week 24 as measured by the MFSAF v2.0 symptom diary and by the MPN-SAF. - PGIC score at each visit where the variable is measured. - Number of subjects with responses according to the 2013 IWG-MRT consensus criteria for treatment response. - Calculation of the PK parameters such as AUC, CL/F, Cmax, and tmax along with summarization of the observed concentration data by timepoint will be performed for both ruxolitinib and itacitinib. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Adverse events will be monitored from the time the subject signs the ICF through the safety follow-up. From baseline through Week 12 From baseline through Week 12 and Week 24 PK: Week 2 and Week 4 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 10 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Austria |
Netherlands |
Switzerland |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
the end of the study will occur when all subjects have completed treatment or discontinued study drug and have completed applicable follow-up assessments. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 5 |
E.8.9.2 | In all countries concerned by the trial days | 0 |